242 related articles for article (PubMed ID: 16355548)
21. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
22. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
24. Darbepoetin alpha coming of age.
Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
[TBL] [Abstract][Full Text] [Related]
25. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
26. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
Pirker R
Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin-stimulating agents: new data yield new insights.
Zitella L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
[No Abstract] [Full Text] [Related]
28. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Waltzman RJ
Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
[No Abstract] [Full Text] [Related]
29. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
30. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
Agrawal V; Mukherjee S; Kosuri R; Dumler F
Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
[TBL] [Abstract][Full Text] [Related]
31. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
Oberhoff C
Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
[TBL] [Abstract][Full Text] [Related]
32. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
Glaspy JA
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy.
Littlewood TJ
Front Radiat Ther Oncol; 2002; 37():34-7. PubMed ID: 11764665
[No Abstract] [Full Text] [Related]
35. Critical appraisal of scientific posters comparing anemia treatments for cancer patients: applying ISPOR Task Force guidelines on methodological quality of retrospective studies.
Demarteau N; Moeremans K; Annemans L;
Crit Rev Oncol Hematol; 2007 Aug; 63(2):91-9. PubMed ID: 17462908
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
37. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
Lynch DM; Slaven T
Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
[No Abstract] [Full Text] [Related]
38. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
Vanscoy GJ
Curr Med Res Opin; 2004 Sep; 20(9):1459-60; author reply 1462-3. PubMed ID: 15383195
[No Abstract] [Full Text] [Related]
39. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
40. Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
Morreale A; Plowman B; DeLattre M; Boggie D; Schaefer M
Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
